Questcor up on Acthar data

Investor's Business Daily

The pharmaceutical company said paid prescriptions of its sole drug, Acthar, dropped from a very strong August, but were still up more than 30% from Sept. '11. Aetna (AET) decided halfway through the month to withdraw coverage of Acthar for all but one indication. Questcor's (QCOR) shares rose 3.3% to 20.96.

View Comments (0)